Efficacy of cefdinir as part of a stepwise antibiotic therapy for community-acquired pneumonia in children

Authors: T.V. Marushko, Doctor of Medical Sciences, Professor, N.P. Glyadelova, Ph.D., R.M. Loboda

National University of Health of Ukraine named after. P.L. Shupyk, KNP KGDKB No. 1, Kyiv


Clinical recommendations, international guidelines, treatment strategy in our country (Order of the Ministry of Health of Ukraine dated August 02, 2022 No. 1380) are aimed at excluding certain groups of patients at risk of developing community-acquired pneumonia with an etiological cause of microorganisms that are not amenable to effective treatment of antimicrobial recommendations. In addition, there are risk groups of patients for whom the possibility of alternative pathogens should be considered. A thorough history to determine potential exposure, together with knowledge of comorbidities and other risk factors, allows the astute clinician to expand the differential diagnosis and be prepared for the lack of improvement in initial therapy. This, in turn, influences the choice of empiric antimicrobial therapy and selective diagnostic testing [1, 6].

Recent analyzes and studies emphasize that, regardless of the dose of antibiotic and the duration of its administration, if starting antimicrobial therapy is received, approximately one in eight children should be prescribed a different antibiotic in the absence of clinical improvement [3]. Patients with community-acquired pneumonia who fail to stabilize or clinically improve after 24-48 hours should be reassessed, with particular attention to unusual causes of pneumonia not treated by standard therapy.

The aim of our study was to study the efficacy and safety of using the drug cefdinir (Rodinir) as part of a stepwise antibiotic therapy in children with community-acquired pneumonia.

Download article in PDF (Ukr)

Аренда яхты